* RAPT Therapeutics press release [https://seekingalpha.com/pr/20296636-rapt-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights] (RAPT [https://seekingalpha.com/symbol/RAPT]): Q3 GAAP EPS of -$0.65 beats by $0.17.
* Reported a net loss of $17.58M.
MORE ON RAPT THERAPEUTICS
* RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria - Slideshow [https://seekingalpha.com/article/4831270-rapt-therapeutics-inc-rapt-discusses-top-line-phase-ii-results-for-rptminus-904-in-chronic]
* RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript [https://seekingalpha.com/article/4831254-rapt-therapeutics-inc-rapt-discusses-top-line-phase-ii-results-for-rptminus-904-in-chronic]
* RAPT Therapeutics prices equity offering at $30 per share [https://seekingalpha.com/news/4506475-rapt-therapeutics-prices-equity-offering-at-30-per-share]
* RAPT Therapeutics announces proposed public offering [https://seekingalpha.com/news/4506334-rapt-therapeutics-announces-proposed-public-offering]
* Seeking Alpha’s Quant Rating on RAPT Therapeutics [https://seekingalpha.com/symbol/RAPT/ratings/quant-ratings]
RAPT Therapeutics GAAP EPS of -$0.65 beats by $0.17
Published 2 days ago
Nov 6, 2025 at 5:27 PM
Positive
Auto